E-Pharmacies Boost Saudi Pharmaceutical Market Expansion

According to the latest market research study published by P&S Intelligence, the Saudi Arabian pharmaceuticals market is poised for significant growth, with projections estimating its value to reach USD 21.8 billion in 2024 and further expand at a compound annual growth rate (CAGR) of 4.5%, culminating in USD 28.3 billion by 2030. This upward trajectory is largely driven by the nation's expanding population and escalating healthcare concerns. In response, the government has been proactive in enhancing and broadening healthcare infrastructure and accessibility, thereby fueling the rapid advancement of the pharmaceutical sector.​

A notable contributor to this growth is the increasing prevalence of chronic diseases, such as respiratory disorders and diabetes, primarily attributed to lifestyle changes. For instance, the International Diabetes Federation reported that in 2021, approximately 4,272,100 out of 24,194,300 adults in Saudi Arabia were living with diabetes. These chronic conditions necessitate ongoing medication for effective treatment and management, thereby amplifying the demand for pharmaceutical products.

To Learn More About this Report

Key Insights

Product Type Analysis

• Prescription Drugs:
• In 2024, prescription drugs are anticipated to constitute 60% of the market share. This dominance is propelled by the rising incidence of chronic diseases, including ischemic heart disease, obesity, and hypertension, which require long-term medication regimens. Additionally, the presence of multinational pharmaceutical companies supplying branded medications through wholesale partners bolsters this segment.
• Over-the-Counter (OTC) Drugs:
• While prescription drugs lead in market share, OTC drugs are experiencing faster growth. This surge is linked to the availability of medications for general conditions, such as common colds and headaches, which consumers can purchase without a doctor's prescription.

Distribution Channel Analysis

• Retail Pharmacies:
• Retail pharmacies are projected to hold a 45% market share in 2024. Their adoption of modern retail practices, such as efficient inventory management, organized store layouts, and enhanced customer service, makes them increasingly appealing to consumers. Moreover, these pharmacies offer the convenience of medication refills without necessitating hospital visits.

Indication Analysis

• Cardiovascular Diseases (CVDs):
• CVDs are expected to account for the highest market revenue. A study indicates an overall CVD prevalence of 1.6% across all provinces in Saudi Arabia, with higher rates among males (1.9%) compared to females (1.4%). Furthermore, the National Library of Medicine identifies CVDs as a leading cause of mortality in the country, responsible for approximately 45.7% of deaths. The chronic nature of many CVDs necessitates long-term treatment and careful management, thereby driving demand for related medications.
• Diabetes:​
• Diabetes is identified as the fastest-growing category within the pharmaceuticals market. The substantial number of adults living with diabetes underscores the escalating demand for effective diabetic treatments and management solutions.

Regional Analysis

• Al-Riyadh:
• Al-Riyadh is leading the market with a 35% share in 2024. This prominence is attributed to its status as a central hub for major pharmaceutical companies and hospitals. The province's sophisticated logistics and cold-chain infrastructure further enhance its attractiveness for pharmaceutical distribution.
• Eastern Region:​
• The Eastern Region is projected to experience a CAGR of 4.8% during the forecast period. This growth is driven by enhancements in healthcare infrastructure and a burgeoning population, both of which contribute to increased demand for pharmaceutical products.

Technological Advancements

E-Pharmacies:​

A significant trend in the Saudi Arabian pharmaceuticals market is the growing utilization of e-pharmacies. In 2022, approximately 92% of the population owned smartphones, facilitating easy access to online medicine ordering platforms. E-pharmacies offer benefits such as convenient access, home deliveries, prescription management solutions, product information, and counseling services, thereby enhancing the consumer experience. Government support for e-commerce and digitalization further propels the growth of e-pharmacies.

Competitive Landscape

The Saudi Arabian pharmaceuticals market is characterized by high competitiveness, with several major players, including Tabuk Pharmaceuticals and Al Tadawi Healthcare, actively participating. Government initiatives promoting local companies, along with insurance and healthcare reforms, have led to an increase in the number of operating players. Intense competition among pharmaceutical companies in pricing strategies, supply chain management, and promotional campaigns further intensifies the market dynamics.

In summary, the Saudi Arabian pharmaceuticals market is on a robust growth trajectory, driven by factors such as an increasing prevalence of chronic diseases, technological advancements like e-pharmacies, and strategic government initiatives aimed at enhancing healthcare infrastructure and accessibility. The market's segmentation across product types, distribution channels, indications, and regions offers diverse opportunities for stakeholders to capitalize on emerging trends and address evolving healthcare needs.

h    107    

w    662.516

107

662.516

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Read More

Knowing About Biological Safety Cabinet and What they Do?

Biological safety cabinet keeps workers safe and also sustaining quality. There is a requirement for regular certification. But what is the exact use of biological safety cabinets. This blog will provide info about the uses, working, and also the types of devices.

BSC’s, are ventilated enclosures in a lab. Within these, employees can handle dangerous specimens with safety. HEPA fan and filter units filter air away from people to direct harmful aerosols out of the cabinets. Furthermore, the fan/filter incessantly recirculates the air. Consequently, the cabinet has clean air. Eventually, the key purpose of a BSC is the safety of the people working in a lab. 

Class I

These protect employee and workspace in labs actively handling powders and chemicals. A front opening on every cabinet lets the clean air in. It moves with the help a built-in exhaust and HEPA filter before entering the unit. At the back side of the work surface, the air leaves the cabinet. The inward flow of the air controls the unsafe aerosols a people might generate within by directing them into filtration elements absorbing them.

Class II

These cabinets provide protection to the workspace, employees and the products present. The air enters the work area from a front aperture. The air inside continues under the work surface and travels up the back plenum. Next, most of the air recirculates through the main HEPA filter. This offers down flow, then the remaining air exits through another filter.

There are some features making it different from the class I cabinet. First, there is a front opening with specific, steady flow of the air inwards. Secondly, vertical, HEPA-filtered unidirectional airflow steadily moves through the key chamber. And thirdly, the exhaust air enters the adjacent laboratory through an external extraction system.

Class III

These are fully airtight enclosure with completely sealed front windows. This separates the employee from the unsafe specimen with a physical barrier, offering ideal protection. 

Workers wear long, heavy duty rubber gloves located on ports in the cabinet. These allow them to operate the product inside without compromising on containment.

For removing materials from the BSC, a side chamber has an airlock transfer hatch. Additionally, there might be a double door autoclave. Any materials removed from the cabinet goes through decontamination. Strict safety protocols are followed through every process, which has this kind of cabinet. This comprise putting on interlock for the doors and autoclave for ensuring that neither door is opened simultaneously as the other.

These are perfect for biosafety laboratories with ratings of 4. These labs have the deadliest biological agents. In these, employees abide by the highest containment and protection practices. Class III BSCs are among the methods in which BSL-4 labs work for protecting people and guarantee total containment.

Coming to a Conclusion 

Eventually, BSCs have a big role to play in maintaining the safety of the workers in the lab. So, it is always essential to check that the functioning of the same is very proper. 

The demand for these biological safety cabinet is on the rise because of the increase in the incidence of chronic diseases, and it will reach a value of USD 507.1 million by the end of this decade.

Read More

What are the Latest Updates on Recombinant Proteins?

Recombinant proteins are gaining popularity due to their pivotal role as essential components in biological systems, facilitating numerous vital processes within cells. These processes encompass gene expression, proliferation, cell growth, nutrient uptake, apoptosis, and intercellular communication.

Understanding Recombinant Proteins

Recombinant proteins refer to proteins that are formed within a host by introducing foreign genes into them through transfection. These proteins represent a novel combination of genes, constituting the DNA. They are constructed from cloned DNA sequences that encode enzymes or proteins. 

Recombinant proteins can be modified to produce pharmaceutical products and other enzymes. They can also be engineered into antibodies for disease treatment and utilized as protein-based polymers for drug delivery. The applications of recombinant proteins extend significantly into tissue engineering and various medical engineering fields.

Latest Updates on Recombinant Proteins

The usage of recombinant proteins is widespread across academic research institutes, pharmaceutical and biopharmaceutical companies, biotechnology companies, and contract research organizations. However, pharmaceutical and biopharmaceutical companies stand as the largest consumers of recombinant proteins, mainly due to their increasing adoption by major manufacturers in drug discovery and target detection efforts.

Moreover, the rising prevalence of various rare disorders, such as neutropenia, multiple sclerosis, cerebral apoplexy, dwarfism, and anemia, is driving the demand for drugs based on recombinant proteins. These agents are also instrumental in developing novel therapies for severe chronic disorders, including cardiovascular diseases, cancer, viral diseases, and endocrine diseases. 

The growing occurrence of such conditions is expected to fuel the need for recombinant protein drugs in the years to come.

Furthermore, advancements in technology are contributing to the expansion of the recombinant proteins  industry with various methods being developed for synthesizing these proteins. These advancements include the production of alternative cell lines and enhanced cell culture techniques, along with the introduction of new expression technologies like baculovirus expression, E. coli expression, and mammalian cell expression. These innovations have streamlined and facilitated the production of recombinant proteins.

Increasing Use of Growth Factors and Chemokines

Among various types of recombinant proteins, growth factors, and chemokines are experiencing significant utilization, particularly in research studies focusing on neurobiology, immunology, COVID-19, cancer, and HIV/AIDS. Growth factors and chemokines are signaling molecules that control the activity of cells in an endocrine, paracrine, or autocrine manner. They bind to receptors, initiating downstream signaling pathways that influence gene transcription within the nucleus, ultimately leading to biological responses.

Widespread Use of Recombinant Proteins in Biologics

The most widespread use of recombinant proteins in the field of drug discovery and development, particularly in biologics. The increasing inclination of biopharma and pharma firms to expand their research and development efforts and product pipelines for biologics and biosimilars, coupled with advancements in bioprocessing science and novel technologies, has driven this growth.

Moreover, the rising demand for biopharmaceuticals and their expanding applications, as well as intensified competition among major companies, further contribute to the prominence of recombinant proteins.

With the prevalence of chronic disorders increasing in emerging economies such as China and India, and substantial public and private funding being directed towards recombinant protein research and development across Asian nations, the demand for recombinant proteins will keep rising, and it will reach a value of USD 3,203.7 million by the end of this decade.

Read More

How Are Genomics Research Projects Driving Microfluidic Devices Demand?

The microfluidic devices market will reach USD 59,785.3 million, advancing at a 17.3% compound annual growth rate, by 2030.

To learn more about this report: https://bit.ly/3OYmHDh

The growth of the industry is attributed to the increasing technological advancements pace and the extension of genomic and proteomic research. Various commercial applications and scientific activities can benefit from methods that allow swift and cheap experiments with a high sensitivity level.

With the advancements in the field of biotechnology recently, several microfluidic technology applications have been identified, such as drug discovery, next-generation sequencing, point-of-care diagnostics, biomarker analysis, and cell analysis. Businesses are developing enhanced devices for numerous applications that have a smaller size, a lesser cost, and a higher sensitivity & speed.

In recent years, North America accounted for the largest industry share, and it will remain the largest in the years to come. This is because of the speedy acceptance of advanced technologies by the major users in the region. In addition, the increasing research & development activities and the existence of key players will boost the growth of the industry, particularly in the U.S.

China is one of the fastest-growing microfluidic devices industry in APAC because of the growing government investment and developing facilities of healthcare. Therefore, the APAC microfluidic devices industry will arise as an attractive industry for businesses producing such medical instruments.

Whereas, the Europe industry is driven by the growing requirements for diagnosis, because of the enhancing facilities of healthcare and the increasing prevalence of illnesses; itself because of the elderly population and lifestyle changes.

It is because of the extensive analytical application and commercial prospects of these devices, as well as the growing life science sector, the microfluidic devices industry will continue to grow in the years to come.

Read More